We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Novel Microbe Biomarkers Reveal Evidence of Radiation Exposure

By LabMedica International staff writers
Posted on 14 Jun 2012
Researchers have identified unique biomarkers that could be used to confirm exposure to damaging radiation in large groups of individuals potentially exposed to unknown and variable doses for the purpose of triage and treatment.

The findings are published in the May 1, 2012, issue of the journal Radiation Research. John E. Baker, PhD, professor of surgery, biochemistry, pharmacology, and toxicology at the Medical College of Wisconsin (Milwaukee, USA), is the lead author of the study.

There is an urgent need for fast, precise, and sensitive diagnostic platforms to validate exposure to radiation and estimate the dose absorbed by individuals. Clinical symptoms do not provide sufficient diagnostic information to triage and treat life-threatening radiation injuries; furthermore, the United States has been found to be unprepared to assess and triage large groups of patients with potential radiation exposure.

In this study, researchers examined the microbes found in rat feces before and after exposure to radiation. Alterations were identified in the levels of 212 genomically unique bacteria, of which 59 are found in humans. Those changes persisted at least 21 days following the exposure to radiation. One particular type of microbe, Proteobacteria, increased nearly 1,000- fold four days following irradiation.

“If there were to be a radiological terrorism scenario, there could be hundreds of thousands of people that would be present around the ground zero area, and limited medical resources available to evaluate their exposure levels,” explained Dr. Baker. “Analyzing microbial signatures in those patients would be a noninvasive way to obtain results in a timely fashion, and allow us to commit resources to patients in need of intervention.”

The PhyloChip assay, developed by Second Genome (San Bruno, CA, USA), was used in this study to examine specific bacterial taxa.

Related Links:

Medical College of Wisconsin



New
Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
New
DNA topoisomerase I ELISA
Anti-Scl-70 ELISA Test
New
Human Papillomavirus Multiplex Assay
Anyplex Ⅱ HPV28 Detection

Latest Molecular Diagnostics News

Simple Blood Draw Helps Diagnose Lung Cancer 10 Times Faster

WHO Approves First Mpox Diagnostic Test for Emergency Use

Clinical Digital PCR System for Oncology Testing Delivers Highly Accurate Diagnostic Results